Tag: Phase 3
Roche partners 10 govt hospitals to strengthen clinical trial capabilities in...
Initiative aligns with CDSCO priorities to boost participation of government sites in Phase 3 and 4 Trials
Sun Pharma’s phase 3 trials of ILUMYA support potential U.S. submission...
Both pivotal studies met their primary endpoint with statistically significant improvements based on ACR20 response rates at Week 24 with tildrakizumab 100 mg (ILUMYA) compared to placebo
Lupin completes Phase 3 trials for Lucentis Biosimilar
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
First ever human patient dosed with Gene Therapy in Ocugen’s Phase...
This first patient dosing marks the beginning of the dose-escalating, observer-blind, Phase 1/2 safety and efficacy study
Phase-3 trial results show COVAXIN is 77.8% effective against symptomatic COVID-19
Efficacy analysis demonstrates COVAXIN to be 93.4% effective against severe symptomatic COVID-19. Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant..................................
COVAXIN demonstrates interim clinical efficacy of 78% in phase 3 trials
The second interim results showed India’s First COVID-19 Vaccine had demonstrated strong primary efficacy against severe COVID-19 disease.......................
Bharat Biotech’s COVAXIN Phase 3 results show interim clinical efficacy of...
Data from 25,800 participants that received the COVAXIN vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well-tolerated. It demonstrated 81% interim efficacy in preventing COVID-19 after the second dose....................
Serum Institute’s ROTASIIL shows great efficacy, included in national immunization program
The international nonprofit PATH partnered with Serum Institute of India to evaluate the vaccine which demonstrated significant efficacy against severe rotavirus gastroenteritis during its Phase 3 trials...........
Sun Pharma achieves breaking results for its Psoriasis drug
The company has achieved primary end point in both Phase-3 studies in patients with moderate-to-severe plaque Psoriasis...
Spain’s Almirall to commercialize Sun Pharma’s Psoriasis drug in Europe
Under terms of the license agreement, the Spanish firm, Almirall will pay Sun Pharma an initial upfront payment of $50 million for.....